Activity Details

0.75 AMA PRA Category 1 Credit(s)
/ MOC point(s)
Released: May 15, 2020
Expires: May 14, 2021
45 minutes to complete

Accredited By

Target Audience

This activity is intended for oncologists, pulmonologists, pathologists, advanced practice nurses, nurse practitioners, and PAs who manage patients with SCLC.

Learning Objectives

  • Describe the role of the immune system in tumor pathogenesis and how immunotherapy can be utilized to modulate the anti-tumor immune response
  • Evaluate current and emerging immunotherapies for the management of small cell lung cancer (SCLC) on the basis of clinical trial safety and efficacy data
  • Incorporate immunotherapy into the management of patients with SCLC where appropriate
  • Identify and manage immune-related adverse events associated with checkpoint inhibitors

Activity Description

In this interactive panel discussion, oncology experts and a patient with SCLC discuss recent advances in the use of immunotherapy for SCLC management. Experts present the latest efficacy data supporting the use of immune checkpoint inhibitors and strategies for managing treatment-related adverse events. An experienced patient with SCLC provides his unique perspective on treatment administration, education, and expectations. The panel concludes by addressing the personalized selection of patients with SCLC who may benefit from immunotherapy.

Statement of Educational Need

Small cell lung cancer is an aggressive form of lung cancer that is historically associated with limited treatment options and low survival rates. However, in the last few years immunotherapies have emerged as effective treatment options for SCLC, particularly in people with extensive-stage disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the efficacy, safety, and tolerability of immunotherapies, the rationale for use in SCLC, and how to incorporate these treatments into SCLC management.


This activity will address the following topics:

  • Role of the immune system in tumor pathogenesis
  • Rationale for immunotherapy in SCLC
  • Brief overview of the mechanism of action of immunotherapy
  • Evidence on the safety and efficacy of approved and emerging immune checkpoint inhibitors
  • Recognizing and managing immune-mediated adverse reactions associated with immunotherapy
  • Description of ongoing and planned clinical trials of immunotherapy for SCLC
  • Identifying patients who may benefit from immunotherapy


Hossein Borghaei, DO, MS (Chair)
Chief, Thoracic Oncology
Professor, Department of Hematology and Oncology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair in Thoracic Malignancies
Fox Chase Cancer Center
Philadelphia, PA

Hossein Borghaei, DO, MS, is the chief of Thoracic Oncology and a professor in the Department of Hematology/Oncology at the Fox Chase Cancer Center in Philadelphia, PA. He earned his medical degree at Philadelphia College of Osteopathic Medicine and completed his residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer. Dr. Borghaei is board certified in medical oncology.

Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the PI of a Phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.

Dr. Borghaei is a member of the thoracic core committee at Eastern Cooperative Oncology Group (ECOG) and, until recently, was a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer panel. He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. Dr. Borghaei is a long-standing member of ASCO, AACR, and NCCN and ECOG thoracic committees. Dr. Borghaei has published in many peer-reviewed publications, including The New England Journal of Medicine, The Lancet Oncology, Lung Cancer, and the Journal of Thoracic Oncology.

Hossein Borghaei, DO, MS, has affiliations with AbbVie, Amgen, AstraZeneca, Axiom, Boehringer Ingelheim, BioNTech, Bristol-Myers Squibb, Cantargia AB, Celgene, Daiichi, EMD-Serono, Genentech, Genmab, GLG, Huya Bio, Lilly, Merck, Novartis, Pfizer, PharmaMar, Regeneron, Takeda (Consultant); Merck/Celgene, Millennium, Bristol-Myers Squibb/Lilly (To Institution) (Contracted Research); Incyte, Takeda, U of Pennsylvania (Data Safety Monitoring Board); Rgenix, Sonnetbio (Stock).

Taofeek K. Owonikoko, MD, PhD, MSCR
Professor and Vice-Chair, Faculty Development
Department of Hematology and Medical Oncology
Chair, Thoracic Malignancies Working Group
Director of Thoracic Oncology
, Discovery & Developmental Therapeutics Program
Winship Cancer Institute
Emory University
Druid Hills, GA

Taofeek K. Owonikoko, MD, PhD, MSCR, is Professor and Vice-Chair for Faculty Development in the Department of Hematology and Medical Oncology and Co-Leader of the Discovery & Developmental Therapeutics Program at the Winship Cancer Institute of Emory University. Dr. Owonikoko received his primary medical training at the Obafemi Awolowo University in Ile-Ife, Nigeria. He completed his residency in anatomic pathology at the Lagos University Teaching Hospital and later proceeded to Dusseldorf, Germany for further training in anatomic pathology at the Heinrich Heine University. He received his PhD degree in anatomic pathology from the Heinrich Heine University, after which he proceeded to the Johns Hopkins University in Baltimore for postdoctoral training in molecular imaging. Dr. Owonikoko is board certified in medical oncology.

Dr. Owonikoko is a world-renowned expert in the treatment of lung cancer. He is particularly interested in advancing the care of and improving the outcomes for small cell lung cancer (SCLC). He leads an active clinical and research program at the Winship Cancer Institute at Emory University looking at new treatment strategies for patients through clinical trials and translational research work in the lab. Dr. Owonikoko has received awards on his leadership, including the IASLC Heine H. Hansen Lectureship Award and the NCI Cancer Clinical Investigator Team Leadership Award. He has also been published in many peer-reviewed journals, including the Journal of Thoracic Oncology, The Cancer Journal, Clinical Cancer Research, and Molecular Oncology.

Taofeek Owonikoko, MD, PhD, MSCR, has affiliations with AbbVie, Amgen, ARMO BioScience, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron Pharmaceutical, Lilly, MedImmune, Merck, Novartis, Sandoz, Seattle Genetics, PharmaMar, Takeda, XCovery (Consulting/Advisory Board); AbbVie, Aeglea Biotherapeutics, Amgen, Astellas Pharma, AstraZenea/MedImmune, Bayer, Bristol-Myers Squibb, Corvus Pharmaceuticals, Fujifilm, G1 Therapeutics, Incyte, Loxo/Lilly, Merck, Novartis, Pfizer, Regeneron, StemCentRx, United Therapeutics, EMD Serono, Roche/Genentech (IRC/DSMB); Cambium Oncology (Stock).

Kristen Kreamer, CRNP, AOCNP, APRN, BC
Nurse Practitioner, Thoracic and Head and Neck Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Kristen Kreamer, CRNP, AOCNP, APRN, BC, is a medical oncology nurse practitioner at Fox Chase Cancer Center in Philadelphia, PA. Ms. Kreamer earned her MS in nursing from Yale University in New Haven, CT, and worked as a clinical nurse specialist for 12 years before completing a post-masters certification as an oncology nurse practitioner at the University of Pennsylvania in Philadelphia, PA.

Ms. Kreamer’s practice includes patients with lung and head and neck malignancies and she also works with the Lung Cancer Screening and Tobacco Treatment programs at Fox Chase. She is a member of the Oncology Nursing Society, the Advanced Practice Society for Hematology/Oncology and Sigma Theta Tau International. Ms. Kreamer has been published in The Journal for Advanced Practitioners in Oncology and other peer-reviewed publications.

Kristen Kreamer, CRNP, AOCNP, APRN, BC, has affiliations with AstraZeneca (Speakers Bureau).

Cedric White (Patient)
Cedric White has nothing to disclose.

Conflict of Interest Policy/Disclosure Statement

AKH planners and reviewers have no financial relationships to disclose.
RMEI Medical Education, LLC planners and managers have no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points 0 patient safety in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must complete the following steps:

Step 1: Review and successfully complete the activity

Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth

Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion

There is no fee to participate.

Your Feedback is Important!


*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This educational activity is supported by independent medical educational grants from AstraZeneca and Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.